RemeGen registers Phase IIIb trial of RC28-E Injection in DME and wAMD
The study, led by RemeGen Co., Ltd., plans to enroll 350 participants and has a planned start date of October 30, 2026. It aims to evaluate the safety profile and explore the efficacy of RC28-E in participants with diabetic macular edema and wet age-related macular degeneration.
Primary source
ClinicalTrials.gov registry record, November 13, 2026
IIIb Trial for RC28-E Injection in Participants With DME and wAMD
Read the source: IIIb Trial for RC28-E Injection in Participants With DME and wAMD clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation